Fosun Pharma (600196.SH) subsidiary passes GMP compliance inspection.

Zhithong Finance and Economics APP News, Fosun Pharma (600196.SH) announced that its wholly-owned subsidiary Shanghai Fuhong Hanlin Biopharmaceutical Co., Ltd. recently received a "Drug GMP Compliance Inspection Notification" issued by the Shanghai Food and Drug Administration. Its production base located in Songjiang District, Shanghai has passed the drug production quality standard compliance inspection for Pertuzumab Injection (China's domestic trade name: Hanbeiyoushi) (i.e. GMP compliance inspection). The inspection covers the raw material (DS) production line, formulation (DP) production line, and packaging line.